- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02871167
Risk of Infertility Related to Adjuvant Chemotherapy for Early Breast Cancer: Oocyte/Embryo Cryopreservation (CHACRY-1501)
Risk of Infertility Related to Adjuvant Chemotherapy for Early Breast Cancer: Oocyte/Embryo Cryopreservation (CHACRY-1501)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Medical Oncology:
- Information and collection of consent,
- Imaging staging,
- Inclusion
- Physical examination
- Contraception advise given
Reproductive medicine center:
- Ovarian reserve assessment: serum anti-mullerian hormone (AMH) measurement and antral follicle count (AFC) by ultrasound.
- Serology syphilis, hepatitis B and C, HIV (human immunodeficiency virus). In case of embryo cryopreservation, same serology determination for the men.
- Infertility risk and fertility preservation techniques information.
- In case of agreement, this technique will be done during the time-interval between surgery and chemotherapy
- Fertility preservation (COH stimulation, triggering and oocyte retrieval)
Adjuvant chemotherapy:
- The chemotherapy regimen is 3 FEC (fluorouracil epirubicin cyclophosphamide) 100 followed by standard chemotherapy (according to local practice) +/- Trastuzumab. Adjuvant chemotherapy may only begin after the oocyte retrieval.
- Usual adjuvant chemotherapy is not changed
During chemotherapy:
- Clinical exam before each cycle of chemotherapy
- AMH, AFC at cycle 6
After chemotherapy:
- Usual patient monitoring in expert center :
physical examination at Month 3 (M3), M6 M9 M12 M18 and M24 and mammography at M9 then annual
- AMH at Month 3 (M3), M6 M9 M12 M18 and M24
- AFC at Month 12 (M12) and M24
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Bondy, France, 93140
- Not yet recruiting
- Hôpital Jean Verdier
-
Bordeaux, France, 33076
- Recruiting
- Centre Aliénor d'Aquitaine, Hôpital Pellegrin
-
Caen, France, 14033
- Recruiting
- CHU de Caen
-
Caen, France, 14076
- Recruiting
- Centre Francois Baclesse
-
Clamart, France, 92140
- Recruiting
- Hôpital Antoine Béclère
-
Dijon, France, 21079
- Recruiting
- CHU de Dijon
-
Dijon, France, 21079
- Recruiting
- Centre Georges François Leclerc
-
La Réunion, France, 97410
- Recruiting
- CHU Réunion Site Sud
-
Lille, France, 59020
- Recruiting
- Centre Oscar Lambret
-
Lille, France, 59037
- Recruiting
- CHRU Hôpital Jeanne de Flandres
-
Limoges, France, 87042
- Recruiting
- Chu Limoges
-
Lyon, France, 69373
- Recruiting
- Centre Leon Berard
-
Lyon, France, 69229
- Recruiting
- CHU LYON
-
Marseille, France, 13005
- Recruiting
- CHU la Conception
-
Marseille, France, 13273
- Recruiting
- Institut Paoli Calmette
-
Montpellier, France, 34298
- Recruiting
- ICM - Val d'Aurelle
-
Montpellier, France, 34295
- Recruiting
- CHRU Montpellier
-
Nancy, France, 54000
- Recruiting
- CHRU de Nancy
-
Paris, France, 75005
- Recruiting
- Institut Curie
-
Paris, France, 75014
- Recruiting
- Hopital Cochin
-
Paris, France, 75020
- Recruiting
- Hopital Tenon
-
Rouen, France, 76038
- Recruiting
- Centre Henri Becquerel
-
Rouen, France, 76031
- Recruiting
- CHU Rouen
-
Saint-Cloud, France, 92210
- Recruiting
- Institut Curie
-
Strasbourg, France, 67091
- Recruiting
- Hôpital Universitaire de Strasbourg
-
Toulouse, France, 31059
- Recruiting
- Oncopole-CHU Toulouse
-
Vandoeuvre les nancy, France, 54519
- Recruiting
- Institut de Cancérologie de Lorraine
-
Villejuif, France, 94805
- Not yet recruiting
- Institut Gustave Roussy
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Women with histologically proven breast cancer
- Aged 18 to 38 years old
- Planned adjuvant chemotherapy
- No prior chemotherapy
- Affiliated to a public health insurance program
- Informed consent signed by the patient
Exclusion Criteria:
- Metastatic breast cancer
- Planned neo-adjuvant chemotherapy
- Hysterectomy
- Exclusive adjuvant hormonotherapy
- Positive serology for syphilis, hepatitis B or C, or VIH
- Contraindication related to use of r-FSH
- Pregnant or breastfeeding patients
Study Plan
How is the study designed?
Design Details
- Primary Purpose: PREVENTION
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Oocyte/embryo cryopreservation
|
After information and consent, patients are addressed to a reproductive medicine center. The COH will be performed according to a standardized protocol between surgery and the start of adjuvant chemotherapy. Follicular growth will be achieved with an antagonist protocol and by using high dose recombinant FSH (r-FSH). The triggering of the final follicular and oocyte maturation will be obtained by a GnRH (Gonadotropin Releasing Hormone) agonist injection in order to minimize the risk of ovarian hyper-stimulation.
Egg or embryo freezing will be performed according to a standardized protocol: slow-freezing process for embryo; vitrification technique for oocytes.
Cryopreserved oocytes and embryos will be stored in the biological bank of each reproductive medicine center (min.
10 years).
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Quality of oocytes: total number of oocytes preserved
Time Frame: after oocyte retrieval (35-36 hours after triptorelin injection)
|
The distribution of the total number of oocytes preserved will be summarized by the mean (standard error) and median (range) and presented with a 95% confidence interval.
|
after oocyte retrieval (35-36 hours after triptorelin injection)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Quality of embryos: total number of embryos preserved
Time Frame: at 44-46 hours post intra-cell sperm injection
|
at 44-46 hours post intra-cell sperm injection
|
|
Type of oocytes
Time Frame: after oocyte retrieval (35-36 hours after triptorelin injection)
|
mature, immature, fractured
|
after oocyte retrieval (35-36 hours after triptorelin injection)
|
Toxicity related to the controlled ovarian stimulation according to NCI CTCAE v4.0 scale
Time Frame: 24 months
|
Toxicities will be tabulated with frequencies and percentages by type of adverse events and by grade
|
24 months
|
Serum AMH measurement
Time Frame: baseline, at the end of the first sequence of chemotherapy, at the last injection of treatment, at Month 3, Month 6, Month 9, Month 12, Month 18 and Month 24
|
baseline, at the end of the first sequence of chemotherapy, at the last injection of treatment, at Month 3, Month 6, Month 9, Month 12, Month 18 and Month 24
|
|
Antral Follicular Count (AFC) measurement
Time Frame: baseline, at month 3, at month 12, at month 24
|
baseline, at month 3, at month 12, at month 24
|
|
Number of Spontaneous or medically assisted pregnancy(ies)
Time Frame: up to 10 years after the end of the study or at 43 years old
|
To measure the degree of project completion of subsequent pregnancy(ies)
|
up to 10 years after the end of the study or at 43 years old
|
Rate of patients wishing for re-utilization of their frozen gametes
Time Frame: up to 10 years after the end of the study or at 43 years old
|
To assess the number of patients wishing for re-utilization of their frozen gametes
|
up to 10 years after the end of the study or at 43 years old
|
Disease-free survival
Time Frame: through study completion, an average of 5 years
|
defined as the interval between inclusion and the first occurrence of local, regional or distant relapse, estimated using the Kaplan-Meier method
|
through study completion, an average of 5 years
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Translational research : circulating nucleic acids quantification: cell-free DNA and microRNAs on blood sample
Time Frame: an average of 6 months
|
before 1st cycle of adjuvant chemotherapy, during the adjuvant chemotherapy (end of first sequence), at the end of adjuvant chemotherapy
|
an average of 6 months
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start
Primary Completion (ANTICIPATED)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- CHACRY-1501
- 2016-000808-28 (EUDRACT_NUMBER)
- PHRC-K14-010 (OTHER_GRANT: INCA)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Breast Cancer
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI); Rutgers Cancer Institute of New JerseyActive, not recruitingStage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast CancerUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedMale Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
Northwestern UniversityEisai Inc.UnknownMale Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative...United States
-
University of WashingtonTerminatedBreast Cancer | Breast Cancer Stage I | Breast Cancer Stage II | Breast Cancer Stage III | Breast Cancer Stage IIB | Breast Cancer Stage IIA | Breast Cancer Stage IIIA | Breast Cancer Stage IIIB | Breast Cancer Stage IIIcUnited States
-
CelgeneCompletedBreast Cancer | Metastatic Breast Cancer | Stage IV Breast Cancer | Triple-negative Breast Cancer | Recurrent Breast Cancer | Breast Tumor | Cancer of the Breast | Triple-negative Metastatic Breast Cancer | Estrogen Receptor- Negative Breast Cancer | HER2- Negative Breast Cancer | Progesterone Receptor- Negative...United States, United Kingdom, Italy, Germany, Spain, Canada, Portugal, Australia, Austria, Greece, Brazil, France
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedHER2-positive Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
University of WashingtonNational Cancer Institute (NCI)CompletedHER2-positive Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Estrogen Receptor-negative Breast Cancer | Estrogen Receptor-positive Breast Cancer | Progesterone Receptor-negative Breast Cancer | Progesterone Receptor-positive Breast...United States
-
University of WashingtonNational Cancer Institute (NCI)CompletedHER2-positive Breast Cancer | Male Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
Sidney Kimmel Cancer Center at Thomas Jefferson...Susan G. Komen Breast Cancer FoundationCompletedStage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast CancerUnited States
-
Ohio State University Comprehensive Cancer CenterCompletedStage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer | Stage III Breast CancerUnited States
Clinical Trials on Controlled ovarian hyperstimulation (COH)
-
Institut Universitari DexeusTerminatedPolycystic Ovary Syndrome | In Vitro FertilizationSpain
-
Kasr El Aini HospitalUnknownRecurrent Implantation Failure
-
Istituto Clinico HumanitasCompletedFertility Disorders | ART
-
GeneScience Pharmaceuticals Co., Ltd.Peking University Third HospitalUnknownPolycystic Ovary SyndromeChina
-
Universitaire Ziekenhuizen KU LeuvenUnknownInfertility | EndometriosisBelgium
-
University Magna GraeciaCompleted
-
Reproductive & Genetic Hospital of CITIC-XiangyaRecruiting
-
Ain Shams Maternity HospitalCompleted
-
Hanoi Medical UniversityRecruiting
-
Instituto Valenciano de Infertilidad, IVI VALENCIARecruitingInfertility, Female | Oocyte MaturationSpain